Testagen

Exactly one verified compound-specific study of Testagen exists. It showed the KEDG peptide entering the nucleus and binding DNA in a sequence-specific manner in HeLa cells. This supports the general epigenetic mechanism claimed for the whole bioregulator class, but it is a mechanism demonstration in a cancer cell line and says nothing about reproductive tissue or testosterone.

The family should not be treated as a single evidence tier. Epitalon is the best-supported member, with telomerase activation findings and a 2025 independent replication at Brunel University in London. Cartalax has in-vitro fibroblast and kidney-cell data but no human trials. Testagen sits at the bottom with one in-vitro DNA-binding study and no reproductive data. Anyone evaluating a specific bioregulator should check that compound's own evidence rather than relying on the reputation of the class.

Most Khavinson peptides are not FDA-approved for human use. They circulate as research compounds sold as not for human consumption, or occasionally as compounded preparations. This applies across the family including Testagen, Vilon, Livagen, Vesugen and Chonluten.

Among the recognised Khavinson bioregulators, Testagen is assessed as having the weakest evidence base. A second caution is added on marketing grounds: testosterone claims are among the most aggressively promoted and least evidence-supported in the entire global supplement market, so a testosterone-adjacent peptide with no reproductive data warrants extra scepticism.

References to Testagen affecting testosterone levels and prostate function in men with prostatitis appear in Russian-language sources, but these cannot be independently audited in English. This is the practical origin of the testosterone marketing claims: they rest on material that Western readers cannot verify, and that has not been replicated.

There is no published controlled human trial for Testagen. More specifically, there are no studies of Testagen on spermatogenesis, Leydig cells, or any reproductive endpoint at all. The compound is assigned to the reproductive system by the framework's organ-mapping logic, not by demonstrated reproductive-tissue data.

Testagen is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid and glycine (KEDG), developed within the Khavinson gerontopeptide programme and assigned to the reproductive system in that framework. It is sold as a research compound and is not approved for human use.

Members are defined by sequence and target organ. Vilon (Lys-Glu, dipeptide) targets thymus and immune function. Livagen (Lys-Glu-Asp-Ala, tetrapeptide) targets liver. Vesugen (Lys-Glu-Asp, tripeptide) targets vascular wall and blood vessels. Chonluten (Glu-Asp-Gly, tripeptide) targets respiratory and lung tissue. Testagen (Lys-Glu-Asp-Gly, tetrapeptide) targets the reproductive system. Epitalon (Ala-Glu-Asp-Gly) targets the pineal gland, and Cartalax targets connective tissue.